# Claude Opus 5.5 (low): Build Litigation Case Timeline — Chronological Event Summary for Breach of Contract and Fraud Defense

> [!NOTE]
> **Unedited model output and AI judge grades.** The deliverables are AI-generated drafts on Harvey LAB's fictional task records. Pass/fail verdicts are the native LAB judges' AI judgments, not human review or accepted corrections. See the [model-runs overview](../../README.md).

[Task audit page](../../../tasks/build-litigation-case-timeline/README.md) · [Pinned task and rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json) · [GPT-6 Luna (xhigh) run](../gpt6luna-xhigh/README.md) · [All runs](../../README.md)

**Model:** `claude-opus-5-5`, reasoning effort `low`. **Run:** `20260926-202411`.

**Native grades:** Sonnet 4.6 passed 60 of 64 criteria; GPT-5.5 passed 60 of 64 criteria. LAB all-pass score: 0 (mean of the judges' all-pass results; a task scores 1 with a judge only if every criterion passes).

## Deliverables

- [litigation-case-timeline.docx](output/litigation-case-timeline.docx) ([read as Markdown](output/litigation-case-timeline.docx.md))

## Grades

Failures are in bold. Each criterion links to both judges' reasoning below.

| Criterion | Title | Sonnet 4.6 | GPT-5.5 |
|---|---|---|---|
| [C-001](#c-001) | Timeline includes EDA execution date of March 15, 2020 | Pass | Pass |
| [C-002](#c-002) | Timeline includes Year 1 performance ($4.3M vs $4.0M minimum) | Pass | Pass |
| [C-003](#c-003) | Timeline includes Year 2 performance ($6.1M vs $5.5M minimum) | Pass | Pass |
| [C-004](#c-004) | Timeline includes June 8, 2022 Holcomb-to-Yee email (Cascade trial run) | Pass | Pass |
| [C-005](#c-005) | Timeline includes August 22, 2022 Holcomb-to-Stanton email (Cascade outperforming) | Pass | Pass |
| [C-006](#c-006) | Timeline includes September 14, 2022 Stanton-to-Fong email (tighten QA) | Pass | Pass |
| [C-007](#c-007) | Timeline includes October 3, 2022 Fong-to-Stanton email (selective QA admission) | Pass | Pass |
| [C-008](#c-008) | Timeline includes December 1, 2022 Holcomb-to-Stanton email (cover story) | Pass | Pass |
| [C-009](#c-009) | Timeline includes December 15, 2022 non-renewal notice deadline | Pass | Pass |
| [C-010](#c-010) | Timeline includes January 3, 2023 Stanton-to-Ivers email (termination strategy) | Pass | Pass |
| [C-011](#c-011) | Timeline includes January 10, 2023 Notice of Material Breach | Pass | Pass |
| [C-012](#c-012) | Timeline includes February 15, 2023 Notice of Termination | Pass | Pass |
| [C-013](#c-013) | Timeline includes February 22, 2023 Harborview breach response | Pass | Pass |
| [C-014](#c-014) | Timeline includes February 28, 2024 Complaint filing with case information | Pass | Pass |
| [C-015](#c-015) | Timeline identifies Breach of Contract cause of action in Complaint | Pass | Pass |
| [C-016](#c-016) | Timeline identifies Breach of Implied Covenant cause of action in Complaint | Pass | **Fail** |
| [C-017](#c-017) | Timeline identifies Fraud cause of action in Complaint | Pass | Pass |
| [C-018](#c-018) | Timeline identifies Tortious Interference cause of action in Complaint | Pass | Pass |
| [C-019](#c-019) | Timeline includes April 15, 2024 Answer and Counterclaim | Pass | Pass |
| [C-020](#c-020) | Timeline includes June 3, 2024 Scheduling Order | Pass | Pass |
| [C-021](#c-021) | Scheduling Order entry references key deadlines | Pass | Pass |
| [C-022](#c-022) | Timeline includes September 30, 2024 document production | Pass | Pass |
| [C-023](#c-023) | Timeline includes October 18, 2024 Holcomb deposition | Pass | Pass |
| [C-024](#c-024) | Timeline includes November 5, 2024 Fong deposition | Pass | Pass |
| [C-025](#c-025) | Timeline includes November 22, 2024 Beckett deposition | Pass | Pass |
| [C-026](#c-026) | Timeline includes December 10, 2024 expert reports exchange | Pass | Pass |
| [C-027](#c-027) | Events are in strict chronological order | Pass | **Fail** |
| [C-028](#c-028) | Timeline entries include source document references | Pass | Pass |
| [C-029](#c-029) | Timeline entries identify parties or individuals involved | **Fail** | Pass |
| [C-030](#c-030) | ISSUE_001: Identifies breach notice was premature (Year 3 not yet complete) | Pass | Pass |
| [C-031](#c-031) | ISSUE_001: Notes termination may be invalid due to premature breach notice | Pass | Pass |
| [C-032](#c-032) | ISSUE_001: Correctly identifies this issue favors plaintiff (Harborview) | Pass | Pass |
| [C-033](#c-033) | ISSUE_002: Identifies selective/discriminatory QA enforcement against Harborview | Pass | Pass |
| [C-034](#c-034) | ISSUE_002: Notes 14 vs. 2 rejection disparity as evidence of bad faith | Pass | Pass |
| [C-035](#c-035) | ISSUE_002: Identifies this as supporting Harborview's fraud/bad faith claims | Pass | Pass |
| [C-036](#c-036) | ISSUE_003: Identifies causation loop — diversion + rejections caused shortfall | Pass | Pass |
| [C-037](#c-037) | ISSUE_003: Notes Harborview could have met minimum absent interference | Pass | Pass |
| [C-038](#c-038) | ISSUE_003: Notes this undermines Greenleaf's counterclaim | Pass | Pass |
| [C-039](#c-039) | ISSUE_004: Flags Stanton-to-Ivers email as potentially privileged | Pass | Pass |
| [C-040](#c-040) | ISSUE_004: Notes risk of inadvertent privilege waiver from production | Pass | Pass |
| [C-041](#c-041) | ISSUE_004: References clawback possibility under FRE 502(b) or similar | Pass | Pass |
| [C-042](#c-042) | ISSUE_005: Identifies Dr. Chakrabarti's 5-year projection as speculative | Pass | Pass |
| [C-043](#c-043) | ISSUE_005: Notes this is a target for summary judgment or Daubert challenge | Pass | Pass |
| [C-044](#c-044) | ISSUE_006: Addresses statute of limitations for fraud claim | Pass | Pass |
| [C-045](#c-045) | ISSUE_006: Notes discovery rule may toll limitations period | **Fail** | **Fail** |
| [C-046](#c-046) | ISSUE_007: Identifies pre-litigation spoliation risk | Pass | Pass |
| [C-047](#c-047) | ISSUE_007: Notes Holcomb's false 'supply chain' explanation as relevant | **Fail** | Pass |
| [C-048](#c-048) | ISSUE_008: Flags ambiguity in 'distribute' re: direct sales vs. third-party | **Fail** | **Fail** |
| [C-049](#c-049) | ISSUE_009: Maps Holcomb emails to deposition for impeachment | Pass | Pass |
| [C-050](#c-050) | ISSUE_010: Identifies EDA auto-renewed for Year 4 (missed non-renewal deadline) | Pass | Pass |
| [C-051](#c-051) | ISSUE_010: Notes termination occurred during renewed term, expanding damages | Pass | Pass |
| [C-052](#c-052) | Summary section includes top 5 critical issues ranked by importance | Pass | Pass |
| [C-053](#c-053) | Summary assesses Greenleaf's exposure on Breach of Contract claim | Pass | Pass |
| [C-054](#c-054) | Summary assesses Greenleaf's exposure on Breach of Implied Covenant claim | Pass | Pass |
| [C-055](#c-055) | Summary assesses Greenleaf's exposure on Fraud claim | Pass | Pass |
| [C-056](#c-056) | Summary assesses Greenleaf's exposure on Tortious Interference claim | Pass | Pass |
| [C-057](#c-057) | Summary includes recommended next steps before filing | Pass | Pass |
| [C-058](#c-058) | Correctly identifies Cascade diversion dollar amounts | Pass | Pass |
| [C-059](#c-059) | Correctly states Harborview's claimed damages breakdown | Pass | Pass |
| [C-060](#c-060) | Correctly states Greenleaf counterclaim damages breakdown | Pass | Pass |
| [C-061](#c-061) | Correctly states Dr. Buckley's finding: 11 of 14 rejections inconsistent | Pass | Pass |
| [C-062](#c-062) | Identifies Fong deposition testimony as relevant to QA issue | Pass | Pass |
| [C-063](#c-063) | Year 3 actual purchases correctly stated as $5.8M | Pass | Pass |
| [C-064](#c-064) | Timeline includes QA rejection period (Sept 2022 – Feb 2023) with $1.4M value | Pass | Pass |

## Judge reasoning

### C-001

Timeline includes EDA execution date of March 15, 2020 ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L19))

- **Sonnet 4.6: Pass.** The timeline includes an entry dated 'Mar. 15, 2020' in Phase I that explicitly states 'EDA executed (Stanton / Beckett). Initial term to Mar. 14, 2023.' and lists the key provisions of the Exclusive Distribution Agreement. This clearly identifies March 15, 2020 as the execution date of the EDA between Greenleaf Organics (Stanton) and Harborview Distribution Partners (Beckett).
- **GPT-5.5: Pass.** The timeline contains a March 15, 2020 entry stating “EDA executed” with Stanton/Beckett, and it identifies key EDA provisions. In context, the EDA is the Exclusive Distribution Agreement between Greenleaf Organics and Harborview Distribution Partners.

### C-002

Timeline includes Year 1 performance ($4.3M vs $4.0M minimum) ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L27))

- **Sonnet 4.6: Pass.** The timeline entry for 'Mar. 15, 2020 -- Mar. 14, 2021' explicitly states 'Year 1: Harborview purchases $4.3M against a $4.0M minimum (+$300K), during COVID.' This matches the criterion exactly: Year 1 period, $4.3M purchased, $4.0M minimum, exceeding by $0.3M ($300K).
- **GPT-5.5: Pass.** The timeline expressly includes a Phase I entry for Mar. 15, 2020–Mar. 14, 2021 stating Year 1 purchases were $4.3M against a $4.0M minimum, exceeding by $300K.

### C-003

Timeline includes Year 2 performance ($6.1M vs $5.5M minimum) ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L35))

- **Sonnet 4.6: Pass.** The timeline entry for March 15, 2021 – March 14, 2022 explicitly states: 'Year 2: $6.1M against $5.5M (+$600K; +42% YoY). No breach notices or QA disputes.' This accurately references Year 2 performance with Harborview purchasing $6.1M against a $5.5M minimum, exceeding by $600K ($0.6M), which matches the criterion exactly.
- **GPT-5.5: Pass.** The timeline expressly includes a Phase I entry for March 15, 2021–March 14, 2022 stating Year 2 purchases of $6.1M against a $5.5M minimum, exceeding by $600K.

### C-004

Timeline includes June 8, 2022 Holcomb-to-Yee email (Cascade trial run) ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L43))

- **Sonnet 4.6: Pass.** The timeline includes an entry dated June 8, 2022 in Phase II that references the Holcomb → Yee email about starting a 'small trial run --- 2 pallets of the Trail Mix Bars' and includes the instruction to 'Keep it quiet for now' as well as 'off the books.' The source is cited as HYS (GRN-004217-18) and Holcomb Dep. §IV. This satisfies all elements of the criterion.
- **GPT-5.5: Pass.** The timeline includes a June 8, 2022 entry stating Holcomb emailed Yee to start a small trial run of 2 pallets of Trail Mix Bars and to “Keep it quiet for now,” with additional context about keeping it informal/off the books.

### C-005

Timeline includes August 22, 2022 Holcomb-to-Stanton email (Cascade outperforming) ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L51))

- **Sonnet 4.6: Pass.** The timeline includes an entry dated August 22, 2022 in Phase II (Cascade Diversion section) that references the Holcomb → Stanton email discussing Cascade moving product faster than Harborview in the Portland metro and recommending 'phasing Harborview out of Portland metro in stages.' The entry explicitly quotes the email and notes Holcomb's awareness of the EDA territorial restriction. This satisfies the criterion.
- **GPT-5.5: Pass.** The timeline includes an August 22, 2022 entry describing Holcomb emailing Stanton that Cascade was moving product faster than Harborview and recommending/phasing or transitioning Harborview out of Portland metro.

### C-006

Timeline includes September 14, 2022 Stanton-to-Fong email (tighten QA) ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L59))

- **Sonnet 4.6: Pass.** The timeline includes an entry dated September 14, 2022 in Phase III that explicitly references the Stanton → Fong email directing her to 'tighten up QA on the Harborview batches' and hold them to 'the highest standard.' The entry quotes the email directly and provides strategic annotation about it.
- **GPT-5.5: Pass.** The timeline includes a September 14, 2022 entry identifying Stanton → Fong and quoting the directive to “tighten up QA on the Harborview batches” and hold them to “the highest standard.”

### C-007

Timeline includes October 3, 2022 Fong-to-Stanton email (selective QA admission) ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L67))

- **Sonnet 4.6: Pass.** The timeline includes an entry dated October 3, 2022 in Phase III (Selective QA Enforcement) that references Fong's email to Stanton. The entry states: 'Applied enhanced screening to lots H-2209 through H-2215. Rejected 4 lots. FYI --- same criteria applied to Cascade lots would have flagged at least 2, but those weren't in the enhanced screening protocol.' It also identifies the specific lots rejected (H-2209, H-2211, H-2213, H-2214, $187K) and names Cascade lots C-2210 and C-2212 as comparable. The date is correct (Oct. 3, 2022) and all key elements of the criterion are present.
- **GPT-5.5: Pass.** The timeline contains an October 3, 2022 entry for Fong → Stanton stating that enhanced screening was applied to lots H-2209 through H-2215, 4 lots were rejected, and the same criteria would have flagged at least 2 Cascade lots that were not in the enhanced screening protocol.

### C-008

Timeline includes December 1, 2022 Holcomb-to-Stanton email (cover story) ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L75))

- **Sonnet 4.6: Pass.** The timeline includes a detailed entry dated December 1, 2022 in Phase II (Cascade Diversion section) referencing the Holcomb → Stanton email. The entry explicitly states: 'Randy is asking why shipments are down. I told him supply chain issues.' and notes Holcomb 'could not identify any supply disruption,' directly addressing the cover story element. The date is correct and the content matches the criterion requirements.
- **GPT-5.5: Pass.** The timeline includes a December 1, 2022 entry for Holcomb to Stanton stating that Randy/Beckett was asking why shipments were down and Holcomb told him it was due to supply chain issues, with strategic annotation about falsity/scienter.

### C-009

Timeline includes December 15, 2022 non-renewal notice deadline ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L83))

- **Sonnet 4.6: Pass.** The timeline includes an entry dated 'Dec. 14, 2022' titled 'Last day for §9.3 non-renewal notice (90 days before Mar. 14, 2023). No notice sent.' The agent notes that the pleadings, Chakrabarti, and Holcomb's email say Dec. 15, while the correct count is Dec. 14. The date December 15, 2022 is explicitly referenced multiple times throughout the document (in the Dec. 1, 2022 entry discussing Holcomb's 'belt-and-suspenders' email flagging the 'December 15' non-renewal deadline, and in Section 5 discrepancy #12 noting 'Dec. 15, 2022 (Compl. ¶49, Chakrabarti, Holcomb email)'). The criterion asks whether the timeline includes December 15, 2022 or references this date as the non-renewal notice deadline. The agent does reference this date explicitly, even while noting the correct date is actually December 14. The criterion is satisfied.
- **GPT-5.5: Pass.** The output references the December 15, 2022 non-renewal deadline multiple times, including noting Holcomb flagged the “December 15” non-renewal deadline and explaining that no notice was sent to prevent auto-renewal, even though the agent also states it believes the correct deadline was December 14.

### C-010

Timeline includes January 3, 2023 Stanton-to-Ivers email (termination strategy) ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L91))

- **Sonnet 4.6: Pass.** The timeline includes a detailed entry dated January 3, 2023 referencing the Stanton→Ivers email (GL-PROD-007834), quoting 'We need to move on terminating Harborview. They're not hitting minimums --- let's use that as the basis.' The entry discusses the privilege issue, the pretext evidence, and the conflicting purchase figures. The date is correct and the content matches the criterion.
- **GPT-5.5: Pass.** The timeline includes a January 3, 2023 entry for Stanton → Ivers (GL-PROD-007834) quoting that Greenleaf needed to move on terminating Harborview because they were not hitting minimums and to “use that as the basis.”

### C-011

Timeline includes January 10, 2023 Notice of Material Breach ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L99))

- **Sonnet 4.6: Pass.** The timeline includes a detailed entry dated January 10, 2023 for the Notice of Material Breach in Phase IV. It states: 'Notice of Material Breach (signed by Holcomb; cc Stanton, Ivers). Claims Year 3 purchases ≈ $4,270,000 (shortfall $2.73M). Demands cure within 30 days by a binding purchase plan or purchases "sufficient to eliminate or substantially reduce" the shortfall.' This correctly identifies the date, the failure to meet the Year 3 minimum purchase commitment, and the 30-day cure demand.
- **GPT-5.5: Pass.** The timeline includes a January 10, 2023 entry titled 'Notice of Material Breach' signed by Holcomb, stating Year 3 purchases were about $4,270,000 with a $2.73M shortfall and demanding cure within 30 days by purchase plan or purchases to reduce/eliminate the shortfall. This satisfies the required date, notice, failure to meet Year 3 minimum purchase commitment, and 30-day cure demand.

### C-012

Timeline includes February 15, 2023 Notice of Termination ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L107))

- **Sonnet 4.6: Pass.** The timeline includes an entry dated February 15, 2023 in Phase IV titled 'Notice of Termination (Stanton) effective Mar. 17, 2023. States purchases ≈ $5.6M, shortfall ≈ $1.4M, "approximately one month remaining."' This matches the criterion requiring an entry for February 15, 2023 for Greenleaf's Notice of Termination terminating the EDA effective March 17, 2023 for uncured material breach.
- **GPT-5.5: Pass.** The timeline contains a February 15, 2023 entry for the Notice of Termination by Greenleaf/Stanton, stating it was effective March 17, 2023 and based on an alleged uncured shortfall/material breach.

### C-013

Timeline includes February 22, 2023 Harborview breach response ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L115))

- **Sonnet 4.6: Pass.** The timeline includes a detailed entry dated February 22, 2023 in Phase IV under 'Breach Notice, Termination and Renewal.' The entry describes Harborview's (DGW) response letter disputing the breach notice as premature and arguing the shortfall was caused by diversion ($1.9M) and QA ($1.4M), and demands withdrawal, cessation of Cascade shipments, accounting, and includes a litigation preservation demand. The date is correct and the content matches the criterion requirements.
- **GPT-5.5: Pass.** The timeline includes a February 22, 2023 entry for Harborview’s response letter stating the breach notice was premature and that the shortfall was caused by Greenleaf’s diversion/reduced shipments and QA issues/rejections, along with related demands.

### C-014

Timeline includes February 28, 2024 Complaint filing with case information ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L123))

- **Sonnet 4.6: Pass.** The agent's output includes an entry dated 'Feb. 28, 2024' in Phase V (Litigation section) stating 'Complaint filed (4 counts; $8,202,000).' The case caption at the top also identifies the court as 'United States District Court --- District of Oregon, Portland Division' and the case number as '3:24-cv-00613-MRH.' The criterion requires an entry for February 28, 2024 for the filing of Harborview's Complaint in U.S. District Court for the District of Oregon, Case No. 3:24-cv-00613-MRH, which is satisfied.
- **GPT-5.5: Pass.** The output identifies the court and case number at the top (United States District Court, District of Oregon, Case No. 3:24-cv-00613-MRH) and includes a Phase V timeline entry dated February 28, 2024 stating that the Complaint was filed.

### C-015

Timeline identifies Breach of Contract cause of action in Complaint ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L131))

- **Sonnet 4.6: Pass.** The agent's output includes a 'Claims' section in the case overview table that explicitly lists Harborview's claims including '(1) breach of contract (exclusivity + wrongful termination)'. Additionally, in Section 4 (Claim-by-Claim Summary Judgment Assessment), the timeline addresses 'Count 1(a): Breach of §3.1 (Cascade diversion)' and 'Count 1(b): Wrongful termination' as breach of contract claims. The Complaint filing entry in Phase V also references '4 counts; $8,202,000' and the claims table identifies breach of contract as the first cause of action. Breach of Contract is clearly identified as one of the causes of action in the Complaint.
- **GPT-5.5: Pass.** The output lists Harborview’s claims near the top, including “(1) breach of contract,” and later discusses Count 1 breach theories. Therefore Breach of Contract is identified as a cause of action in the Complaint/work product.

### C-016

Timeline identifies Breach of Implied Covenant cause of action in Complaint ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L139))

- **Sonnet 4.6: Pass.** In the 'Claims' section of the case summary table, the agent lists Harborview's claims as: '(1) breach of contract (exclusivity + wrongful termination); (2) breach of implied covenant; (3) fraud / intentional misrepresentation; (4) tortious interference.' The breach of implied covenant is explicitly identified as one of the causes of action. Additionally, in Section 4, the claim-by-claim assessment includes 'Count 2: Implied covenant' as a separate entry. The criterion asks whether the timeline entry for the Complaint identifies Breach of Implied Covenant of Good Faith and Fair Dealing as one of the causes of action, and it does.
- **GPT-5.5: Fail.** The output does list “breach of implied covenant” in the preliminary Claims summary and later claim-by-claim section, but the chronological timeline entry for the Complaint itself only says “Complaint filed (4 counts; $8,202,000)” and does not identify Breach of Implied Covenant as a cause of action.

### C-017

Timeline identifies Fraud cause of action in Complaint ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L147))

- **Sonnet 4.6: Pass.** In the case overview table under 'Claims', the agent explicitly lists Harborview's claims including '(3) fraud / intentional misrepresentation'. This clearly identifies the Fraud cause of action in the Complaint.
- **GPT-5.5: Pass.** The output lists Harborview's claims and expressly identifies “fraud / intentional misrepresentation” as Count 3, and later analyzes “Count 3: Fraud.”

### C-018

Timeline identifies Tortious Interference cause of action in Complaint ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L155))

- **Sonnet 4.6: Pass.** The agent's output explicitly lists Tortious Interference as one of Harborview's claims in the case overview table: 'Harborview: (1) breach of contract (exclusivity + wrongful termination); (2) breach of implied covenant; (3) fraud / intentional misrepresentation; (4) tortious interference.' Additionally, Count 4 is labeled 'Tortious interference' in the claim-by-claim summary judgment assessment section. The Complaint filing entry in Phase V also references '4 counts; $8,202,000' and the document thoroughly discusses tortious interference throughout.
- **GPT-5.5: Pass.** The output lists Harborview’s claims as including “(4) tortious interference” and later includes “Count 4: Tortious interference,” satisfying the requirement that Tortious Interference be identified as a cause of action in the Complaint.

### C-019

Timeline includes April 15, 2024 Answer and Counterclaim ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L163))

- **Sonnet 4.6: Pass.** The timeline includes an entry dated April 15, 2024 in Phase V (Litigation) that states: 'Answer, 10 affirmative defenses, Counterclaim ($1.2M) (ECF 12).' The strategic annotation notes that several averments are contradicted by discovery. The $1.2M counterclaim is explicitly mentioned, and the date matches April 15, 2024. The counterclaim is also described in the case overview table as 'breach of § 5.2 minimum purchase commitment --- $1,200,000 ($408,000 lost profit + $792,000 consequential).' This satisfies the criterion.
- **GPT-5.5: Pass.** The timeline includes a Phase V entry dated Apr. 15, 2024 for Greenleaf’s Answer and Counterclaim, identifying the Counterclaim as $1.2M. Elsewhere in the output, the counterclaim is described as based on breach of § 5.2 minimum purchase commitment / Year 3 shortfall.

### C-020

Timeline includes June 3, 2024 Scheduling Order ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L171))

- **Sonnet 4.6: Pass.** The agent's output includes an entry dated 'May 21 / May 28 / June 3, 2024' in Phase V of the timeline, explicitly referencing the 'Joint Rule 26(f) Report; Rule 16 conference; Scheduling Order entered' with source 'SO'. The June 3, 2024 date for the Scheduling Order is correctly included and matches the criterion.
- **GPT-5.5: Pass.** The output includes the June 3, 2024 Scheduling Order in multiple places, including the litigation calendar stating “Scheduling Order, Dkt. entered June 3, 2024” and a timeline entry “May 21 / May 28 / June 3, 2024 — Joint Rule 26(f) Report; Rule 16 conference; Scheduling Order entered.”

### C-021

Scheduling Order entry references key deadlines ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L179))

- **Sonnet 4.6: Pass.** The Scheduling Order entry in Section 2 (Litigation Calendar) explicitly references all three deadlines: discovery cutoff January 15, 2025 ('Close of fact AND expert discovery; all depositions complete'), dispositive motions March 1, 2025 ('Dispositive motions due (Rule 56)'), and trial June 16, 2025 ('Jury trial (7--10 days)'). At least two of the three required deadlines are clearly referenced.
- **GPT-5.5: Pass.** The output’s Scheduling Order/litigation calendar references all three specified deadlines: discovery cutoff January 15, 2025, dispositive motions due March 1, 2025, and jury trial June 16, 2025.

### C-022

Timeline includes September 30, 2024 document production ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L187))

- **Sonnet 4.6: Pass.** The timeline includes an entry dated 'Sept. 30, 2024' in Phase V (Litigation) that states: 'Greenleaf production (≈ 12,400 docs), including SF emails, HYS emails, QA Log and GL-PROD-007834 (Stanton→Ivers).' This matches the criterion requiring an entry for September 30, 2024 for Greenleaf's production of approximately 12,400 documents.
- **GPT-5.5: Pass.** The timeline includes a Phase V entry dated Sept. 30, 2024 stating Greenleaf produced approximately 12,400 documents, including key emails, QA Log, and GL-PROD-007834.

### C-023

Timeline includes October 18, 2024 Holcomb deposition ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L195))

- **Sonnet 4.6: Pass.** The timeline includes an entry dated October 18, 2024 for the Holcomb deposition in Phase V (Litigation section), noting '187 pp.' and listing key admissions. The date matches exactly.
- **GPT-5.5: Pass.** The timeline includes an entry dated Oct. 18, 2024 stating “Holcomb deposition (187 pp.)” and identifies Derek Holcomb in the witness matrix as deposed on Oct. 18, 2024.

### C-024

Timeline includes November 5, 2024 Fong deposition ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L203))

- **Sonnet 4.6: Pass.** The timeline includes an entry dated November 5, 2024 for the Fong deposition in Phase V (Litigation section): 'Nov. 5, 2024 — Fong deposition. Privilege instruction on the Jan. 3 email; question withdrawn but preserved.' The date is correct and the entry is present.
- **GPT-5.5: Pass.** The timeline includes a litigation entry dated Nov. 5, 2024 stating “Fong deposition” / “Fong deposition. Privilege instruction on the Jan. 3 email,” identifying Lisa Fong’s deposition on the correct date.

### C-025

Timeline includes November 22, 2024 Beckett deposition ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L211))

- **Sonnet 4.6: Pass.** The agent's output includes an entry dated November 22, 2024 in Phase V (Litigation) that states: 'Beckett deposition (per Chakrabarti; no summary in file).' This correctly identifies the date and the event (Beckett deposition), satisfying the criterion.
- **GPT-5.5: Pass.** The timeline includes a Phase V entry dated Nov. 22, 2024 stating that Beckett was deposed, with note that no summary is in the file.

### C-026

Timeline includes December 10, 2024 expert reports exchange ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L219))

- **Sonnet 4.6: Pass.** The timeline includes a December 10, 2024 entry in Phase V (Litigation) that explicitly covers both expert reports: 'Dec. 10, 2024 | Defendant's expert deadline. Buckley report (defense QA): 3 of 14 rejections justified ($301,300); 11 unjustified ($1,098,700); rates 16.3% vs. 2.6% (86 vs. 78 lots); p < 0.005. Chakrabarti report (plaintiff damages): $8,202,000.' Both Dr. Buckley and Dr. Chakrabarti's reports are correctly dated December 10, 2024.
- **GPT-5.5: Pass.** The timeline includes a Phase V entry dated December 10, 2024 identifying both the Buckley defense QA expert report and the Chakrabarti plaintiff damages expert report, with descriptions of each. The date is correct and both experts are included.

### C-027

Events are in strict chronological order ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L227))

- **Sonnet 4.6: Pass.** The main timeline in Section 3 is organized into phases (I through V) and within each phase, events are presented in chronological order. Phase I covers 2014–March 2022, Phase II covers June 2022–February 2023, Phase III covers September 2022–February 2023, Phase IV covers January–March 2023, and Phase V covers February 2024–present. Within each phase, dates proceed from earliest to latest. However, there is an overlap between Phase II (June 2022–February 2023) and Phase III (September 2022–February 2023), meaning events from September 2022 onward appear in both phases simultaneously rather than in a single unified chronological sequence. For example, the Sept. 6, 2022 Holcomb→Yee email appears in Phase II, while the Sept. 12, 2022 lot rejection appears in Phase III — these are interleaved in time but presented in separate sections. Within each phase the ordering is correct, but the overall timeline is not a single strict chronological sequence since Phase II and Phase III overlap in time. That said, the phases themselves are ordered chronologically and within each phase events are in order. The question is whether the 'main timeline section' requires a single unified sequence or allows thematic sub-sections. The phases overlap (Phase II and III both cover Sept 2022–Feb 2023), so events are not in strict chronological order across the entire timeline — e.g., Sept. 19, 2022 appears in Phase II (Cascade shipments Sept–Nov) and also in Phase III (enhanced protocol begins Sept. 19). The structure splits contemporaneous events into separate phases, which means the overall sequence is not strictly chronological. However, within each phase, the ordering is correct. Given that the criterion asks about the 'main timeline section' presenting events in strict chronological order, and the phases overlap causing events from the same time period to appear in different sections rather than a unified sequence, this could be considered out of strict chronological order. Nevertheless, reviewing more carefully: Phase II ends with 'Dec 2022–Feb 2023' entries, and Phase III also has entries through Feb 2023. The Sept 19 entry in Phase II (Cascade shipments Sept–Nov) and the Sept 19 entry in Phase III (enhanced protocol begins) are contemporaneous events split across phases. Within each phase the dates are sequential. The overall document presents a coherent chronological narrative even if split by theme. I'll consider this a pass since within each phase events are in order and the phases themselves proceed chronologically, with the overlap being a thematic organizational choice rather than events being out of sequence within the timeline itself.
- **GPT-5.5: Fail.** FAIL: The main timeline is generally chronological by phase, but it contains events that are not in strict chronological order. For example, in Phase III the row dated “Oct. 7 / Oct. 21, 2022” is placed before the row dated “Oct. 17, 2022,” meaning an Oct. 21 event appears before an Oct. 17 event. Phase IV also places “≈ Feb. 9, 2023” before a “Jan. 10 -- Feb. 15, 2023” event range. These prevent a finding of strict chronological order.

### C-028

Timeline entries include source document references ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L235))

- **Sonnet 4.6: Pass.** Examining the timeline entries across all phases (I through V), virtually every entry includes source document references in the 'Source' column. Phase I entries cite EDA, Ans., Compl., Holcomb Dep., Fong Dep., Buckley, etc. Phase II entries cite HYS, Holcomb Dep., Chakrabarti, etc. Phase III entries cite Log, SF, Buckley, Fong Dep., etc. Phase IV entries cite NMB, NOT, HV Ltr, EDA, Ans., Holcomb Dep., Chakrabarti, SI, etc. Phase V entries cite Compl., SO, Holcomb Dep., Fong Dep., Buckley, Chakrabarti, etc. Nearly every single timeline entry has at least one source document cited from the 15-document set. The percentage of entries with source citations is well above 80%, easily satisfying the criterion.
- **GPT-5.5: Pass.** The master chronological timeline contains a dedicated Source column and virtually every event entry cites one or more source documents from the listed 15-document set (e.g., EDA, Complaint, Answer, Scheduling Order, emails, deposition summaries, expert reports, QA log). Additional deadline/calendar entries also generally reference the Scheduling Order or other record documents. This comfortably exceeds the 80% threshold.

### C-029

Timeline entries identify parties or individuals involved ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L243))

- **Sonnet 4.6: Fail.** I need to evaluate whether at least 80% of timeline entries identify by name the parties or individuals involved in each event. Looking at the timeline entries across all phases: Phase I entries: 1. 2014/2016/2019 - mentions Greenleaf, Harborview, Cascade, Fong, Holcomb - NAMES PRESENT 2. Mar 1, 2020 - QA Manual - no specific individual named (just Buckley as source) - NO NAMES 3. Mar 15, 2020 - EDA executed - Stanton/Beckett named - NAMES PRESENT 4. Mar 15, 2020-Mar 14, 2021 - Harborview purchases - parties named - NAMES PRESENT 5. Mar 15, 2021-Mar 14, 2022 - Holcomb, Beckett named - NAMES PRESENT 6. Jan 1, 2022 - QA Manual v3.2 - no individual named - NO NAMES 7. Mar 15, 2022 - Year 3 begins - no individual named - NO NAMES Phase II entries: 8. June 8, 2022 - Holcomb → Yee - NAMES PRESENT 9. June 10, 2022 - Yee, Holcomb named - NAMES PRESENT 10. June 22, 2022 - First Cascade shipment - no individual named - NO NAMES 11. June-Aug 2022 - Cascade shipments - no individual named - NO NAMES 12. Aug 22, 2022 - Holcomb → Stanton - NAMES PRESENT 13. Aug 23, 2022 - Stanton → Holcomb - NAMES PRESENT 14. Sept 6, 2022 - Holcomb → Yee - NAMES PRESENT 15. Sept-Nov 2022 - Cascade shipments - no individual named - NO NAMES 16. Dec 2022-Feb 2023 - Cascade shipments - no individual named - NO NAMES Phase III entries: 17. Sept 12, 2022 - Lot H-2201 rejected - no individual named - NO NAMES 18. Sept 14, 2022 - Stanton → Fong - NAMES PRESENT 19. Sept 15, 2022 (9:12am) - Fong → Stanton - NAMES PRESENT 20. Sept 15, 2022 (10:03am) - Stanton → Fong - NAMES PRESENT 21. Sept 15, 2022 - Log shows H-2202 - no individual named - NO NAMES 22. Sept 19, 2022 - Enhanced protocol begins - no individual named - NO NAMES 23. Oct 1-3, 2022 - Rejections - no individual named - NO NAMES 24. Oct 3, 2022 - Fong → Stanton - NAMES PRESENT 25. Oct 7/Oct 21, 2022 - H-2211, H-2215 rejected - no individual named - NO NAMES 26. Oct 17, 2022 - Cascade lot rejected - no individual named - NO NAMES 27. Late Oct-Nov 2022 - Beckett pressing Holcomb - NAMES PRESENT 28. Nov 2-Dec 19, 2022 - Log rejections - no individual named - NO NAMES 29. Dec 1, 2022 - Holcomb → Stanton - NAMES PRESENT 30. Dec 14, 2022 - Last day for non-renewal notice - no individual named - NO NAMES 31. Late Dec 2022 - Stanton call with Ivers - NAMES PRESENT 32. Jan 3, 2023 - Stanton → Ivers - NAMES PRESENT 33. Jan 9/23/Feb 13, 2023 - Log rejections - no individual named - NO NAMES Phase IV entries: 34. Jan 10, 2023 - Notice of Material Breach (signed by Holcomb; cc Stanton, Ivers) - NAMES PRESENT 35. ~Feb 9, 2023 - Cure period ends - no individual named - NO NAMES 36. Jan 10-Feb 15, 2023 - Implied Harborview purchases - Harborview named (party) - PARTIAL 37. Feb 15, 2023 - Notice of Termination (Stanton) - NAMES PRESENT 38. Feb 22, 2023 - Harborview (DGW) response - Holcomb, Fong named - NAMES PRESENT 39. ~Mar 8, 2023 - Compliance deadline passes - no individual named - NO NAMES 40. Mar 14, 2023 - Year 3 and Initial Term end - no individual named - NO NAMES 41. Mar 15, 2023 - Renewal Term begins - no individual named - NO NAMES 42. Mar 17, 2023 - Termination effective - no individual named - NO NAMES 43. Apr-Dec 2023 - Harborview mitigation - Harborview named, Chakrabarti - PARTIAL Phase V entries: 44. Feb 28, 2024 - Complaint filed - no individual named - NO NAMES 45. ~Mar 2024 - Litigation hold - Holcomb named - NAMES PRESENT 46. Apr 15, 2024 - Answer filed - no individual named - NO NAMES 47. May 21/28/June 3, 2024 - Rule 26(f)/16 - no individual named - NO NAMES 48. June 17/24, 2024 - Initial disclosures - no individual named - NO NAMES 49. Aug 1, 2024 - Deadline to amend - Cascade mentioned - PARTIAL 50. Aug 2024 - Chakrabarti engaged - Chakrabarti named - NAMES PRESENT 51. Sept 30, 2024 - Greenleaf production - Holcomb, Fong named - NAMES PRESENT 52. Oct 18, 2024 - Holcomb deposition - NAMES PRESENT 53. Nov 5, 2024 - Fong deposition - NAMES PRESENT 54. Nov 12, 2024 - Fong deposition summary - Fong, Buckley named - NAMES PRESENT 55. Nov 22, 2024 - Beckett deposition - NAMES PRESENT 56. Dec 1, 2024 - Plaintiff's expert disclosure - Chakrabarti named - NAMES PRESENT 57. Dec 10, 2024 - Buckley and Chakrabarti reports - NAMES PRESENT 58. Dec 20, 2024 - Rebuttal reports due - no individual named - NO NAMES 59. Jan 15, 2025 - Discovery closes - Stanton, Yee named - NAMES PRESENT 60. Feb 1, 2025 - Daubert motions - no individual named - NO NAMES 61. Mar 1, 2025 - Dispositive motions - no individual named - NO NAMES Let me count: Total entries: approximately 61 Entries WITH names: approximately 1, 3, 4, 5, 8, 9, 12, 13, 14, 18, 19, 20, 24, 27, 29, 31, 32, 34, 37, 38, 45, 50, 51, 52, 53, 54, 55, 56, 57, 59 = about 30 entries Entries WITHOUT names: approximately 2, 6, 7, 10, 11, 15, 16, 17, 21, 22, 23, 25, 26, 28, 30, 33, 35, 36(partial), 39, 40, 41, 42, 43(partial), 44, 46, 47, 48, 49(partial), 58, 60, 61 = about 31 entries That's roughly 30/61 = ~49% of entries having names. This is well below the 80% threshold. However, I should reconsider - many entries reference parties by name (Harborview, Greenleaf, Cascade) even if not individual persons. Let me re-evaluate with party names counting: Entries that mention at least a party name (Harborview, Greenleaf, Cascade) or individual: - Most entries do reference at least one party or individual by name when describing the event. Let me re-examine more carefully: - Entry 2 (Mar 1, 2020 QA Manual): mentions Buckley as source but not in the event description itself - NO - Entry 6 (Jan 1, 2022 QA Manual): no party/individual - NO - Entry 7 (Mar 15, 2022 Year 3): no individual, but references EDA sections - NO - Entry 10 (June 22, 2022 First Cascade shipment): mentions Cascade - YES - Entry 11 (June-Aug 2022 Cascade shipments): mentions Cascade, Holcomb Dep. - YES - Entry 15 (Sept-Nov 2022): mentions Cascade - YES - Entry 16 (Dec 2022-Feb 2023): mentions Cascade, Harborview - YES - Entry 17 (Sept 12, 2022 Lot H-2201): mentions Buckley in conflict note - PARTIAL - Entry 21 (Sept 15 Log): no individual - NO - Entry 22 (Sept 19): mentions Fong, Stanton in source - PARTIAL; the event itself says "Enhanced protocol begins on Harborview lots" - Harborview named - YES - Entry 23 (Oct 1-3): mentions Harborview in the lot names - PARTIAL - Entry 25 (Oct 7/21): no individual in event - NO - Entry 26 (Oct 17): mentions Cascade - YES - Entry 28 (Nov 2-Dec 19): no individual - NO - Entry 30 (Dec 14): no individual - NO - Entry 33 (Jan 9/23/Feb 13): no individual - NO - Entry 35 (~Feb 9): no individual - NO - Entry 36 (Jan 10-Feb 15): mentions Harborview - YES - Entry 39 (~Mar 8): mentions Harborview - YES - Entry 40 (Mar 14): mentions Harborview - YES - Entry 41 (Mar 15): mentions Greenleaf - YES - Entry 42 (Mar 17): no individual - NO - Entry 43 (Apr-Dec 2023): mentions Harborview, Chakrabarti - YES - Entry 44 (Feb 28, 2024): no individual - NO - Entry 46 (Apr 15, 2024): no individual - NO - Entry 47 (May 21/28/June 3): no individual - NO - Entry 48 (June 17/24): no individual - NO - Entry 49 (Aug 1): mentions Cascade - YES - Entry 58 (Dec 20): no individual - NO - Entry 60 (Feb 1): mentions Chakrabarti - YES - Entry 61 (Mar 1): no individual - NO With party names counting, let me recount: With names (party or individual): entries 1,3,4,5,8,9,10,11,12,13,14,15,16,18,19,20,22,24,26,27,29,31,32,34,36,37,38,39,40,41,43,45,49,50,51,52,53,54,55,56,57,59,60 = approximately 43 Without names: entries 2,6,7,17,21,23,25,28,30,33,35,42,44,46,47,48,58,61 = approximately 18 That's 43/61 = ~70%, still below 80%. Actually, let me look more carefully at some of the "no names" entries: - Entry 17 (Sept 12, 2022): "Lot H-2201 rejected under the Standard protocol (moisture 12.3% vs. 12.0% max; $86,400). The Log notes this was the last Standard-protocol lot before the directive." - No individual named in the event itself. - Entry 21 (Sept 15, 2022): "Log shows H-2202 inspected under the Enhanced protocol (passed)." - No individual. - Entry 22 (Sept 19, 2022): "Enhanced protocol begins on Harborview lots. H-2203 rejected (seal integrity; $71,250). The same week, increased Cascade routing begins." - Harborview named, Cascade named - YES - Entry 23 (Oct 1-3): "Rejections under the Log: H-2207...H-2208...H-2209..." - No individual named. - Entry 25 (Oct 7/21): "H-2211 rejected...H-2215 rejected..." - No individual. - Entry 26 (Oct 17): "Cascade lot C-2218 rejected..." - Cascade named - YES - Entry 28 (Nov 2-Dec 19): "Log rejections: H-2220...H-2223...H-2226...H-2230...H-2233..." - No individual. - Entry 30 (Dec 14): "Last day for §9.3 non-renewal notice" - No individual. - Entry 33 (Jan 9/23/Feb 13): "Log rejections H-2237...H-2240...H-2245..." - No individual. - Entry 35 (~Feb 9): "Cure period ends per NOT" - No individual. - Entry 42 (Mar 17): "Termination effective" - No individual. - Entry 44 (Feb 28, 2024): "Complaint filed (4 counts; $8,202,000)." - No individual. - Entry 46 (Apr 15, 2024): "Answer, 10 affirmative defenses, Counterclaim ($1.2M) (ECF 12)." - No individual. - Entry 47 (May 21/28/June 3): "Joint Rule 26(f) Report; Rule 16 conference; Scheduling Order entered." - No individual. - Entry 48 (June 17/24): "Initial disclosures; ESI meet-and-confer." - No individual. - Entry 58 (Dec 20): "Rebuttal expert reports due." - No individual. - Entry 60 (Feb 1): "Daubert / FRE 702 motions due" - mentions Chakrabarti in annotation - YES - Entry 61 (Mar 1): "Dispositive motions due (Rule 56)" - No individual. So entries without any party or individual name: 2, 6, 7, 17, 21, 23, 25, 28, 30, 33, 35, 42, 44, 46, 47, 48, 58, 61 = 18 entries Total entries: ~61 Entries with names: ~43 Percentage: ~70% This is below the 80% threshold. The criterion requires at least 80% of timeline entries to identify by name the parties or individuals involved. With approximately 70% meeting this criterion, the output fails. However, I want to be more careful about what counts as a "timeline entry." The main timeline entries are in the chronological tables in Sections 3 and the calendar in Section 2. Let me focus on Section 3 (the Master Chronological Timeline) as the primary timeline. Section 3 has entries across Phases I-V. Let me count more carefully just the Phase I-IV entries (the substantive timeline, not the litigation calendar): Phase I (7 entries): 1. 2014/2016/2019 - Greenleaf, Harborview, Cascade, Fong, Holcomb - YES 2. Mar 1, 2020 - no individual - NO 3. Mar 15, 2020 - Stanton, Beckett - YES 4. Mar 15, 2020-Mar 14, 2021 - Harborview - YES 5. Mar 15, 2021-Mar 14, 2022 - Holcomb, Beckett - YES 6. Jan 1, 2022 - no individual - NO 7. Mar 15, 2022 - no individual - NO Phase II (9 entries): 8. June 8, 2022 - Holcomb, Yee - YES 9. June 10, 2022 - Yee, Holcomb - YES 10. June 22, 2022 - no individual (Cascade mentioned as entity) - PARTIAL/YES 11. June-Aug 2022 - Cascade, Holcomb Dep. - YES 12. Aug 22, 2022 - Holcomb, Stanton - YES 13. Aug 23, 2022 - Stanton, Holcomb - YES 14. Sept 6, 2022 - Holcomb, Yee - YES 15. Sept-Nov 2022 - Cascade, Holcomb - YES 16. Dec 2022-Feb 2023 - Cascade, Harborview - YES Phase III (13 entries): 17. Sept 12, 2022 - no individual, Buckley in annotation - NO 18. Sept 14, 2022 - Stanton, Fong - YES 19. Sept 15, 2022 (9:12am) - Fong, Stanton - YES 20. Sept 15, 2022 (10:03am) - Stanton, Fong - YES 21. Sept 15, 2022 - no individual - NO 22. Sept 19, 2022 - Harborview, Cascade - YES 23. Oct 1-3, 2022 - no individual - NO 24. Oct 3, 2022 - Fong, Stanton, Cascade - YES 25. Oct 7/Oct 21, 2022 - no individual - NO 26. Oct 17, 2022 - Cascade - YES 27. Late Oct-Nov 2022 - Beckett, Holcomb - YES 28. Nov 2-Dec 19, 2022 - no individual - NO 29. Dec 1, 2022 - Holcomb, Stanton, Beckett, Greenleaf - YES 30. Dec 14, 2022 - no individual - NO 31. Late Dec 2022 - Stanton, Ivers - YES 32. Jan 3, 2023 - Stanton, Ivers - YES 33. Jan 9/23/Feb 13, 2023 - no individual - NO Phase IV (10 entries): 34. Jan 10, 2023 - Holcomb, Stanton, Ivers - YES 35. ~Feb 9, 2023 - no individual - NO 36. Jan 10-Feb 15, 2023 - Harborview - YES 37. Feb 15, 2023 - Stanton - YES 38. Feb 22, 2023 - Harborview, DGW, Holcomb, Fong - YES 39. ~Mar 8, 2023 - Harborview - YES 40. Mar 14, 2023 - Harborview - YES 41. Mar 15, 2023 - Greenleaf - YES 42. Mar 17, 2023 - no individual - NO 43. Apr-Dec 2023 - Harborview, Chakrabarti - YES Phase V (18 entries): 44. Feb 28, 2024 - no individual - NO 45. ~Mar 2024 - Greenleaf, Holcomb - YES 46. Apr 15, 2024 - no individual - NO 47. May 21/28/June 3, 2024 - no individual - NO 48. June 17/24, 2024 - no individual - NO 49. Aug 1, 2024 - Cascade - YES 50. Aug 2024 - Chakrabarti - YES 51. Sept 30, 2024 - Greenleaf, Holcomb, Fong - YES 52. Oct 18, 2024 - Holcomb - YES 53. Nov 5, 2024 - Fong - YES 54. Nov 12, 2024 - Fong, Buckley - YES 55. Nov 22, 2024 - Beckett, Chakrabarti - YES 56. Dec 1, 2024 - Chakrabarti - YES 57. Dec 10, 2024 - Buckley, Chakrabarti - YES 58. Dec 20, 2024 - no individual - NO 59. Jan 15, 2025 - Stanton, Yee - YES 60. Feb 1, 2025 - Chakrabarti - YES 61. Mar 1, 2025 - no individual - NO Total entries: 61 Entries with names (party or individual): 2,6,7,17,21,23,25,28,30,33,35,42,44,46,47,48,58,61 = 18 without names Entries with names: 61 - 18 = 43 Percentage: 43/61 = 70.5% This is below 80%, so the verdict should be FAIL. But wait - I should reconsider whether the Section 2 calendar entries count as "timeline entries" for this criterion. The task says "Chronological Event Summary" and the criterion says "timeline entries." The Section 2 calendar is also part of the timeline. Let me check if including those changes the calculation significantly. Section 2 has about 9 entries: - Dec 5, 2024: Fong named - YES - Dec 20, 2024: no individual - NO - Jan 15, 2025: Stanton, Yee, Chakrabarti, Buckley named - YES - Feb 1, 2025: Chakrabarti named - YES - Mar 1, 2025: no individual - NO - Apr 15, 2025: no individual - NO - May 5, 2025: Chakrabarti named - YES - May 12/19, 2025: no individual - NO - June 16, 2025: no individual - NO Adding these: 4 with names, 5 without Total: 65 entries, 47 with names = 72.3% Still below 80%. The verdict is FAIL.
- **GPT-5.5: Pass.** The timeline consistently identifies the relevant actors for the substantive events, repeatedly naming Harborview, Greenleaf, Cascade, Stanton, Holcomb, Fong, Beckett, Yee, and counsel where applicable. While some procedural deadlines or QA-log entries are less actor-specific, the vast majority of entries identify the parties or individuals involved, meeting the 80% threshold.

### C-030

ISSUE_001: Identifies breach notice was premature (Year 3 not yet complete) ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L251))

- **Sonnet 4.6: Pass.** The agent's output explicitly identifies that the January 10, 2023 Notice of Material Breach was issued 63 days before Year 3 ended (March 14, 2023), and that §5.3 measures the minimum 'during the full applicable Purchase Year.' This is flagged as 'Harborview's cleanest cross-motion argument' in the Executive Summary (Finding #1) and is detailed in the Phase IV timeline entry for Jan. 10, 2023, as well as in Section 4.3 on §9.2 analysis. The output clearly identifies the timing problem that the breach notice was premature because Year 3 had not yet concluded.
- **GPT-5.5: Pass.** The output expressly states that the January 10, 2023 Notice of Material Breach claimed failure to meet the Year 3 minimum while Year 3 did not end until March 14, 2023, noting the notice was issued 63 days before year-end and describing it as premature under §5.3/§9.2.

### C-031

ISSUE_001: Notes termination may be invalid due to premature breach notice ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L259))

- **Sonnet 4.6: Pass.** The agent's output explicitly connects the premature breach notice to the invalidity of the February 15, 2023 termination notice in multiple places. In Finding #1 of the Executive Summary, it notes that §9.2's last sentence voids a termination notice 'issued prior to the occurrence of an actual material breach,' and that Year 3 ended March 14, 2023 while the termination notice issued February 15, 2023. In the Phase IV timeline entry for Feb. 15, 2023, it states the notice was '(1) Issued before any "actual material breach" (Year 3 still open), so void under §9.2's last sentence.' In Section 4.3, it explicitly addresses this as Harborview's strongest cross-motion point. The output clearly and repeatedly connects the premature breach notice to the conclusion that the termination was legally defective/invalid.
- **GPT-5.5: Pass.** The output explicitly discusses that the January 10 breach notice was premature because Year 3 had not ended and the minimum purchase breach had not yet fully materialized, and it connects this to the February 15 termination notice being legally defective/void under §9.2 because it was issued before an actual material breach occurred.

### C-032

ISSUE_001: Correctly identifies this issue favors plaintiff (Harborview) ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L267))

- **Sonnet 4.6: Pass.** The agent's output clearly and repeatedly identifies the premature breach notice / potentially invalid termination issue as favoring Harborview (the plaintiff) and hurting Greenleaf (the defense). In Finding #1 of the Executive Summary, it states this is 'Harborview's cleanest cross-motion argument.' In the claim-by-claim assessment for Count 1(b) Wrongful termination, it rates Greenleaf's SJ prospects as LOW and Harborview's cross-motion risk as HIGH. In Section 4.3, it explicitly states the §9.2 last sentence ('notice issued prior to the occurrence of an actual material breach ... shall be of no force or effect') is 'Harborview's strongest cross-motion point.' The timeline entry for Feb. 15, 2023 (Notice of Termination) is rated ADVERSE (from Greenleaf's perspective), confirming it hurts the defense. The output consistently and unambiguously identifies this issue as favoring the plaintiff.
- **GPT-5.5: Pass.** The output clearly identifies the premature breach notice/invalid termination issue as adverse to Greenleaf and favorable to Harborview, calling it Harborview’s strongest/cleanest cross-motion argument and assigning adverse impact to Greenleaf.

### C-033

ISSUE_002: Identifies selective/discriminatory QA enforcement against Harborview ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L275))

- **Sonnet 4.6: Pass.** The agent's output extensively identifies the selective/discriminatory QA enforcement against Harborview. It specifically documents the September 14, 2022 Stanton-to-Fong directive ordering enhanced screening 'on all lots destined for Harborview,' Fong's September 15 email describing the enhanced thresholds and warning rejections would rise 'not necessarily because the product is bad,' Stanton's response directing it be 'targeted to Harborview batches,' and Fong's October 3, 2022 email explicitly stating that 'same criteria applied to Cascade lots would have flagged at least 2, but those weren't in the enhanced screening protocol.' The output flags these as key adverse evidence, notes the QA Manual v3.2 §2.1.4 forbade destination-based screening, and includes this pattern prominently in the executive summary, timeline, claim assessment, and witness matrix.
- **GPT-5.5: Pass.** The output explicitly identifies selective/discriminatory QA enforcement against Harborview, including Stanton's September 14 directive to tighten QA on Harborview batches, the September 15 confirmation to keep enhanced screening targeted to Harborview, and Fong's October 3 admission that Cascade lots would have been flagged under the same enhanced criteria but were not subject to that protocol.

### C-034

ISSUE_002: Notes 14 vs. 2 rejection disparity as evidence of bad faith ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L283))

- **Sonnet 4.6: Pass.** The agent's output explicitly references the 14 vs. 2 rejection disparity in multiple places. In the Key Witness Matrix section under Lisa Fong's entry, it states her admissions include '14 vs. 2' and 'I was told to focus on Harborview.' Additionally, in Section 4.6 Damages table, it references Buckley's finding of '11 of 14 rejections inconsistent' and the statistical disparity. In the Fong deposition section of Phase V, it notes 'Admissions: CEO directive; enhanced criteria applied only to Harborview; 14 vs. 2.' The output clearly identifies this 14 vs. 2 disparity as evidence supporting bad faith and the implied covenant/fraud claims, satisfying the criterion.
- **GPT-5.5: Pass.** The output explicitly notes the QA disparity, including Fong deposition admissions of “enhanced criteria applied only to Harborview; 14 vs. 2” and elsewhere frames the selective QA evidence as supporting implied covenant/bad faith and fraud theories. It also discusses the statistical disparity in Buckley’s rates and record-discrepancy sections.

### C-035

ISSUE_002: Identifies this as supporting Harborview's fraud/bad faith claims ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L291))

- **Sonnet 4.6: Pass.** The agent's output explicitly and repeatedly connects the selective QA enforcement to Harborview's fraud, intentional misrepresentation, and breach of implied covenant of good faith claims, identifying these as problems for Greenleaf's defense. For example: (1) The Aug. 23 Stanton email is annotated as supporting 'intent for implied covenant, fraud, punitive damages'; (2) The Sept. 14 Stanton→Fong email is flagged as 'ADVERSE' and connected to the fraud/implied covenant claims; (3) The Oct. 3 Fong email is described as 'The key admission for the implied covenant and fraud claims'; (4) The claim-by-claim assessment explicitly rates Count 2 (implied covenant) and Count 3 (fraud) and discusses how the QA evidence supports them; (5) The executive summary notes the QA campaign supports 'intent for implied covenant, fraud, punitive damages and the improper means element of interference.' The connection is made clearly and repeatedly throughout the document.
- **GPT-5.5: Pass.** The output repeatedly links selective/enhanced QA enforcement against Harborview to implied covenant/bad faith and fraud theories, e.g., stating Stanton's QA-related emails support intent for implied covenant and fraud, calling Fong's Oct. 3 email a key admission for implied covenant and fraud, and identifying these facts as adverse/problematic for Greenleaf's summary judgment defense.

### C-036

ISSUE_003: Identifies causation loop — diversion + rejections caused shortfall ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L299))

- **Sonnet 4.6: Pass.** The output explicitly identifies the causation loop in multiple places. In Finding #4 of the Executive Summary, it states: 'Diversion alone ($1.9M) plus actual purchases ($5.8M) = $7.7M, which is above the $7.0M minimum without counting any QA rejection.' Section 4.1 (Causation Arithmetic) provides a detailed table showing that actual purchases of $5.8M plus Cascade diversion of $1.9M equals $7.7M (above the minimum), and that adding Buckley-unjustified QA rejections of $1.1M brings the total to $8.8M. The output explicitly states 'The shortfall disappears without any QA theory. This is the decisive prevention fact against the counterclaim.' The timeline entries for the Cascade diversion and QA rejection phases also repeatedly note how these combined to cause the shortfall, including the Sept. 6 email showing supply was redirected away from Harborview simultaneously with the enhanced QA protocol. The output clearly identifies that Greenleaf's own conduct (diversion ~$1.9M + rejections ~$1.4M = ~$3.3M) caused or contributed to Harborview's Year 3 shortfall of $1.2M below the $7.0M minimum.
- **GPT-5.5: Pass.** The output expressly identifies that Greenleaf diverted about $1.9M to Cascade and rejected about $1.4M in Harborview shipments, totaling about $3.3M, and ties those acts to Harborview’s $1.2M Year 3 shortfall. It includes causation arithmetic showing $5.8M actual purchases plus $1.9M diversion exceeds the $7.0M minimum, and $5.8M plus $3.3M equals $9.1M, supporting the conclusion that Greenleaf’s own conduct caused or contributed to the shortfall.

### C-037

ISSUE_003: Notes Harborview could have met minimum absent interference ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L307))

- **Sonnet 4.6: Pass.** The agent's output explicitly presents the calculation in Section 4.1 (Causation Arithmetic — Year 3 Shortfall), showing '+ Diversion + all QA (plaintiff): $5.8M + $3.3M = $9.1M: +$2.1M' above the $7.0M minimum. The output also states in Finding #4 of the Executive Summary: 'Diversion alone ($1.9M) plus actual purchases ($5.8M) = $7.7M, which is above the $7.0M minimum without counting any QA rejection.' The $9.1M figure and the conclusion that the shortfall disappears absent Greenleaf's interference are clearly presented, satisfying the criterion.
- **GPT-5.5: Pass.** The output explicitly presents the required causation calculation: actual Year 3 purchases of $5.8M plus $1.9M Cascade diversion and $1.4M QA-denied product equals $9.1M, well above the $7.0M minimum. It also notes that diversion alone would have brought Harborview to $7.7M and that this undermines Greenleaf’s breach/counterclaim theory under prevention/causation.

### C-038

ISSUE_003: Notes this undermines Greenleaf's counterclaim ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L315))

- **Sonnet 4.6: Pass.** The agent's output explicitly and repeatedly discusses how Greenleaf's own actions (the Cascade diversion of $1.9M and the selective QA rejections) caused the Year 3 shortfall, and directly states this undermines the counterclaim. For example, in Finding #4: 'Causation defeats the counterclaim even on conservative numbers. Diversion alone ($1.9M) plus actual purchases ($5.8M) = $7.7M, which is above the $7.0M minimum without counting any QA rejection.' The causation arithmetic table in Section 4.1 explicitly shows '+ Cascade diversion only: $5.8M + $1.9M = $7.7M: +$0.7M — The shortfall disappears without any QA theory. This is the decisive prevention fact against the counterclaim.' The claim-by-claim assessment also rates the counterclaim as LOW for Greenleaf's SJ prospects and HIGH for Harborview cross-motion risk, noting 'Greenleaf withheld $3.3M (diversion $1.9M alone suffices)' and references the prevention doctrine. The output clearly and explicitly states that Greenleaf's own actions caused the shortfall and that this undermines the counterclaim.
- **GPT-5.5: Pass.** The output explicitly discusses that Greenleaf's own diversion/QA conduct caused or prevented Harborview from meeting the Year 3 minimum, stating that “Causation defeats the counterclaim,” that diversion plus actual purchases exceeds the $7.0M minimum, and that the prevention doctrine undermines Greenleaf’s $1.2M shortfall counterclaim.

### C-039

ISSUE_004: Flags Stanton-to-Ivers email as potentially privileged ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L323))

- **Sonnet 4.6: Pass.** The agent's output extensively discusses the January 3, 2023 Stanton→Ivers email (GL-PROD-007834) and explicitly flags it as potentially privileged. In Section 3 (Phase III timeline), the entry for Jan. 3, 2023 states: 'Privilege issue: produced Sept. 30, 2024. Privilege was first asserted at the Nov. 5 deposition, but no FRE 502(b) clawback is documented.' In Section 4.5, there is a dedicated table row for 'Stanton → Ivers email (Jan. 3, 2023), GL-PROD-007834' discussing the privilege issue in detail, including FRE 502(b) requirements and recommended clawback actions. Action Item #1 also prioritizes sending a clawback notice for this document. The privilege concern is clearly and repeatedly raised throughout the output.
- **GPT-5.5: Pass.** The output explicitly identifies the Jan. 3, 2023 Stanton-to-Ivers email (GL-PROD-007834) as a privilege issue, noting it was produced, privilege was later asserted, no clawback documented, and recommending clawback/privilege-log actions. It therefore flags the communication as potentially attorney-client privileged.

### C-040

ISSUE_004: Notes risk of inadvertent privilege waiver from production ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L331))

- **Sonnet 4.6: Pass.** The agent's output extensively discusses the inadvertent production of the Stanton→Ivers email (GL-PROD-007834) and the associated privilege waiver risk. In Section 4.5 (Privilege and Preservation Issues Requiring Immediate Action), the output notes that the email was produced on September 30, 2024, that privilege was first asserted 36+ days later at the November 5 deposition, that no FRE 502(b) clawback is documented, and that the delay and use at deposition weigh toward waiver. It also discusses the crime-fraud exception and at-issue waiver risks. The output recommends immediate action to send a formal clawback notice. This issue is also flagged in the timeline entries for September 30, 2024 and November 5, 2024, and in Action Item #1. The criterion is clearly satisfied.
- **GPT-5.5: Pass.** The output expressly identifies the Stanton→Ivers privileged email (GL-PROD-007834) as having been produced in Greenleaf’s September 30, 2024 production, notes that privilege was asserted later with no documented clawback, and discusses FRE 502(b), waiver risk, and recommended clawback actions.

### C-041

ISSUE_004: References clawback possibility under FRE 502(b) or similar ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L339))

- **Sonnet 4.6: Pass.** The agent's output explicitly references FRE 502(b) in multiple places. In Section 4.5 (Privilege and Preservation Issues), it states 'FRE 502(b) requires reasonable precautions and prompt rectification' and recommends 'Send a formal clawback notice now under Rule 26(b)(5)(B) and any protective order.' It also references the possibility of a Rule 502(d) order in the litigation calendar and procedural sections. The output clearly mentions the clawback possibility and the specific remedial steps to take regarding the Stanton→Ivers email (GL-PROD-007834).
- **GPT-5.5: Pass.** The output expressly discusses the privileged Stanton→Ivers email, notes no clawback is documented, references FRE 502(b), Rule 502(d), protective order/clawback stipulation, and recommends sending a formal clawback notice under Rule 26(b)(5)(B).

### C-042

ISSUE_005: Identifies Dr. Chakrabarti's 5-year projection as speculative ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L347))

- **Sonnet 4.6: Pass.** The agent's output explicitly identifies Dr. Chakrabarti's 5-year horizon as speculative in multiple places. In Section 4.6 (Damages), under 'Lost future profits,' the output states: '(a) A five-year horizon (Years 4–8) on a contract renewable one year at a time, with 90-day non-renewal at will, is speculative as a matter of law.' It also recommends 'Partial SJ limiting recovery to the single Renewal Term (Mar. 17, 2023 – Mar. 14, 2024): ≈ $0.94M–$1.0M on her own inputs.' This is further reinforced in the Executive Summary (Finding #7) and in the Daubert motion discussion. The criterion is clearly satisfied.
- **GPT-5.5: Pass.** The output expressly identifies Dr. Chakrabarti’s $5.8M lost future profits as based on a five-year horizon/Years 4–8 and flags it as speculative because the EDA renewed only in one-year terms with 90-day non-renewal rights. It also recommends limiting recovery to the single renewal term.

### C-043

ISSUE_005: Notes this is a target for summary judgment or Daubert challenge ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L355))

- **Sonnet 4.6: Pass.** The agent's output explicitly identifies Dr. Chakrabarti's 5-year lost profits projection as a target for both Daubert challenge and summary judgment. In Section 1 (Executive Summary), it states: 'A Daubert / Rule 37(c) motion against Dr. Chakrabarti, due by the February 1, 2025 Daubert deadline... is the key companion motion.' In Section 4.6, it specifically attacks the 5-year horizon: '(a) A five-year horizon (Years 4–8) on a contract renewable one year at a time, with 90-day non-renewal at will, is speculative as a matter of law.' In Section 7 (Action Items), Priority 3 explicitly states: 'prepare a Rule 37(c)(1) / Daubert motion' targeting the '$5.8M lost profits.' The output also recommends 'Partial SJ limiting recovery to the single Renewal Term' as an alternative. The criterion is clearly satisfied.
- **GPT-5.5: Pass.** The output explicitly identifies Dr. Chakrabarti’s five-year lost-profits horizon as speculative and repeatedly frames it as a Daubert/Rule 37 and partial summary judgment target, including recommendations to limit recovery to the one-year renewal term and challenge the damages model.

### C-044

ISSUE_006: Addresses statute of limitations for fraud claim ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L363))

- **Sonnet 4.6: Pass.** The output explicitly addresses the statute of limitations in Section 4.4 ('Limitations, Pleading and Equitable Defenses'). It states: 'ORS 12.110 (2 years): The earliest alleged act is June 8, 2022. The Complaint was filed Feb. 28, 2024, less than 2 years after every act. The discovery-rule debate is academic. Maintaining the defense in SJ papers risks credibility.' This directly discusses the ORS 12.110 limitations period, notes the fraudulent conduct began June 8, 2022, confirms the Complaint was filed February 28, 2024, and addresses the discovery rule (calling it 'academic' because all acts fall within 2 years of filing). The output also references the discovery rule issue again in Section 5 (#16), noting that Harborview's claim of first suspecting after termination is contradicted by earlier evidence, which is relevant to the discovery rule analysis. The criterion is satisfied.
- **GPT-5.5: Pass.** The output discusses limitations for the fraud claim multiple times, identifying ORS 12.110 as a 2-year period, noting the alleged acts began June 8, 2022 and occurred through the relevant 2022–2023 period, and that the Complaint filed February 28, 2024 was within two years of every alleged act. It also expressly considers the discovery-rule issue, stating it is academic because the claim is timely even without relying on discovery.

### C-045

ISSUE_006: Notes discovery rule may toll limitations period ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L371))

- **Sonnet 4.6: Fail.** The agent's output does address the discovery rule in Section 4.4 ('Limitations, Pleading and Equitable Defenses'), but only to dismiss it as 'academic' because all acts fall within 2 years of the February 28, 2024 filing date. The agent states: 'The earliest alleged act is June 8, 2022. The Complaint was filed Feb. 28, 2024, less than 2 years after every act. The discovery-rule debate is academic.' The criterion requires the output to discuss that the discovery rule may toll the fraud statute of limitations and that Harborview may not have discovered the selective QA enforcement and Cascade diversion until the September 30, 2024 document production or some earlier point, potentially making the fraud claim timely despite the 2-year statute. The agent does not analyze this scenario — it does not discuss the possibility that Harborview's discovery of the fraud (selective QA enforcement, Cascade diversion concealment) might have occurred at a later date that could affect the limitations analysis, nor does it discuss the September 30, 2024 production as a potential discovery date for tolling purposes. The agent's treatment is the opposite of what the criterion requires: rather than noting the discovery rule could help Harborview, it dismisses the discovery rule as irrelevant. The criterion specifically asks whether the output discusses the discovery rule as potentially making the fraud claim timely — the agent does not do this in any meaningful way.
- **GPT-5.5: Fail.** The output mentions ORS 12.110 and says the discovery-rule debate is academic because all alleged acts occurred within two years of filing. It does not discuss that the discovery rule may toll the fraud limitations period based on Harborview not discovering the selective QA enforcement and Cascade diversion until the September 30, 2024 document production or an earlier discovery point. Thus the required tolling analysis is absent.

### C-046

ISSUE_007: Identifies pre-litigation spoliation risk ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L379))

- **Sonnet 4.6: Pass.** The agent's output explicitly addresses spoliation and preservation concerns in multiple places. In Section 4.5 (Privilege and Preservation Issues Requiring Immediate Action), it notes that the preservation demand came on February 22, 2023, but the litigation hold was not issued until approximately March 2024—about 13 months later. It flags Rule 37(e) spoliation/adverse inference exposure and notes Holcomb was vague on retention/deletion policies. It also references the duty to preserve triggered by the February 22, 2023 preservation demand (and arguably earlier dates like December 1, 2022 or January 3, 2023). The Phase V timeline entry for March 2024 explicitly states 'About 13 months after the preservation demand. Holcomb was vague on retention policy. Rule 37(e) spoliation / adverse-inference exposure.' Action Item #10 calls for a preservation audit. This clearly identifies the gap between relevant events (June 2022–March 2023) and the litigation hold (March 2024), notes the duty to preserve arose before the formal filing, and flags the risk that documents may have been destroyed under routine retention policies before the hold was implemented.
- **GPT-5.5: Pass.** The output expressly raises preservation/spoliation concerns: it notes a litigation hold was not issued until around March 2024, about 13 months after Harborview’s February 22, 2023 preservation demand and after the key June 2022–March 2023 events. It states the preservation duty was triggered no later than February 22, 2023, flags Rule 37(e) spoliation/adverse-inference exposure, references vague retention/deletion practices, and recommends auditing custodial collections and retention practices. This satisfies the criterion.

### C-047

ISSUE_007: Notes Holcomb's false 'supply chain' explanation as relevant ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L387))

- **Sonnet 4.6: Fail.** The criterion requires that the output connect Holcomb's false 'supply chain' explanation (December 1, 2022 email) to spoliation concerns or consciousness of guilt, specifically noting that if communications about the Cascade relationship were deleted, this could compound the evidentiary problem. Looking at the output: 1. The December 1, 2022 Holcomb email is discussed in Phase II of the timeline, where it notes: 'Shows knowledge of falsity (fraud scienter). Holcomb could not identify any supply disruption.' It is labeled MIXED and connected to fraud scienter and the 'no justifiable reliance' argument. 2. The output separately discusses spoliation/preservation issues in Section 4.5 and the action items, noting the late litigation hold (~March 2024 vs. February 22, 2023 preservation demand), Rule 37(e) exposure, and the need to audit 'Cascade communications, text messages, "general distribution codes" invoicing.' 3. In the Phase V litigation section, the March 2024 litigation hold entry notes: 'Rule 37(e) spoliation / adverse-inference exposure. Audit custodial collections now (Holcomb, Stanton, Fong, logistics, finance "general distribution codes").' However, the output does NOT explicitly connect the false supply chain explanation in the December 1 email to spoliation concerns or consciousness of guilt in a way that links these two elements together. The December 1 email is discussed for fraud scienter and reliance, while spoliation is discussed separately without referencing the false supply chain story as evidence of consciousness of guilt that compounds the spoliation problem. The criterion specifically requires connecting the false supply chain explanation to spoliation concerns or noting that deleted Cascade communications would compound the evidentiary problem. This specific connection is not made in the output.
- **GPT-5.5: Pass.** The output specifically discusses the Dec. 1, 2022 Holcomb email, notes that the supply-chain explanation was false and evidences knowledge of falsity/scienter and pretext. It also separately flags preservation/spoliation risk for Cascade communications, including Holcomb’s vague retention/deletion testimony and Rule 37(e) exposure. This sufficiently connects the false explanation to consciousness of guilt/evidentiary concerns and notes deleted Cascade communications could worsen the issue.

### C-048

ISSUE_008: Flags ambiguity in 'distribute' re: direct sales vs. third-party ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L395))

- **Sonnet 4.6: Fail.** The agent's output extensively discusses the §3.1 exclusivity clause and the Cascade diversion, noting that §3.1 bars Greenleaf from appointing 'directly or through any third party' any 'other distributor, dealer, reseller.' The output focuses on Cascade as a competing distributor and analyzes whether the clause covers third-party distributors. However, the output does not identify or discuss the specific ambiguity asked about in the criterion: whether 'exclusive rights to distribute' covers only distribution through third-party distributors or also encompasses direct sales by Greenleaf itself to retailers in the territory. The criterion specifically asks whether the output notes that direct-to-retailer sales by Greenleaf may present a different legal question from shipments to Cascade. The agent never raises this distinction or flags this ambiguity anywhere in the document. The analysis treats the Cascade situation as the primary §3.1 issue without exploring whether Greenleaf making direct sales to retailers (as opposed to appointing a competing distributor) would also violate the exclusivity clause or present a different interpretive question.
- **GPT-5.5: Fail.** The output clearly states that shipments to Cascade, a competing distributor, likely violate §3.1 and discusses Greenleaf’s attempted “third-party distribution only” construction as applied to Cascade. However, it does not flag the specific ambiguity required by the criterion: whether “exclusive rights to distribute” also bars Greenleaf’s own direct sales to retailers in the territory, as distinct from appointing or using third-party distributors/resellers. Nor does it note that direct-to-retailer sales may present a different legal question. Thus the required scope ambiguity is not discussed.

### C-049

ISSUE_009: Maps Holcomb emails to deposition for impeachment ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L403))

- **Sonnet 4.6: Pass.** The agent's output extensively maps Holcomb's internal emails to his deposition testimony for impeachment purposes. Specifically: (1) The June 8, 2022 'keep it quiet / off the books' email is flagged in the Phase II timeline entry, with the annotation noting that Holcomb's deposition testimony that the phrase meant avoiding 'confusion with the sales team' is contradicted by the full email language, and this is listed as impeachment evidence. (2) The August 22, 2022 transitioning email is analyzed in the timeline with the annotation that Holcomb called it 'brainstorming' but the email contains a staged phase-out plan, and that it shows contemporaneous awareness of the territorial restriction, undercutting his 'relied on internal guidance' testimony. (3) The December 1, 2022 'supply chain issues' email is flagged in the timeline noting Holcomb 'could not identify any supply disruption' at deposition, and in the Key Witness Matrix section Holcomb is described as 'Heavily impeached: keep it quiet / off the books, supply chain, internal guidance.' The Section 4 claim assessment also references Holcomb's key admissions at deposition. The output clearly and repeatedly juxtaposes these emails with his deposition testimony for impeachment purposes.
- **GPT-5.5: Pass.** The output expressly maps all three specified Holcomb emails to his October 18, 2024 deposition testimony and flags impeachment contradictions: June 8 “keep it quiet/off the books” versus his deposition explanation about avoiding sales-team confusion; August 22 transition/EDA-territory email versus his “brainstorming” and “internal guidance” testimony; and December 1 “supply chain issues” statement versus his inability to identify any supply disruption. It also summarizes Holcomb as heavily impeached based on these documents.

### C-050

ISSUE_010: Identifies EDA auto-renewed for Year 4 (missed non-renewal deadline) ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L411))

- **Sonnet 4.6: Pass.** The agent's output explicitly identifies that no non-renewal notice was sent by the December 14/15, 2022 deadline, and states that as a consequence the EDA auto-renewed on March 15, 2023 for Year 4. This appears in multiple places: in Finding #7 of the Executive Summary ('No notice was sent by the deadline (correctly December 14, 2022, not December 15 as the Complaint, Chakrabarti and Holcomb say), so the EDA arguably auto-renewed on March 15, 2023'), in the Phase IV timeline entry for Dec. 14, 2022 ('Consequence: auto-renewal on Mar. 15, 2023 (Harborview)'), and in the Phase IV entry for Mar. 15, 2023 ('Renewal Term (Year 4) begins by operation of §9.3, absent timely non-renewal ($7.5M minimum)'). The criterion is clearly satisfied.
- **GPT-5.5: Pass.** The output explicitly states that no non-renewal notice was sent by the 90-day deadline (noting Dec. 14/15 discrepancy), and concludes the EDA auto-renewed on March 15, 2023 for the Year 4 renewal term through March 14, 2024.

### C-051

ISSUE_010: Notes termination occurred during renewed term, expanding damages ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L419))

- **Sonnet 4.6: Pass.** The agent's output explicitly notes that the EDA auto-renewed on March 15, 2023 (due to no timely non-renewal notice), and that the March 17, 2023 termination occurred two days into the Renewal Term (Year 4). The output discusses this in multiple places: in Finding #7 of the Executive Summary ('caps expectation damages at the one-year Renewal Term'), in the Phase IV timeline entry for March 15, 2023 ('Renewal Term (Year 4) begins by operation of §9.3'), in the March 17, 2023 entry ('Harborview's damages theory depends on this. Greenleaf's damages-limitation argument: the maximum lost term is Mar. 17, 2023 -- Mar. 14, 2024'), and in the damages table (Section 4.6) which discusses limiting recovery to the single Renewal Term. The output clearly identifies that termination occurred during the renewed Year 4 term and that this affects damages calculations, specifically that Harborview's damages extend into the Year 4 renewal period (though Greenleaf argues this should be capped at one year). This satisfies the criterion.
- **GPT-5.5: Pass.** The output explicitly states that no non-renewal notice was sent, so the EDA arguably auto-renewed on March 15, 2023; it then notes the March 17, 2023 termination was effective two days into the Renewal Term and that Harborview's damages theory depends on this, with potential lost-term damages running through the Year 4 renewal period. It also discusses capping lost-profit exposure at the one-year Renewal Term rather than Year 3 only.

### C-052

Summary section includes top 5 critical issues ranked by importance ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L427))

- **Sonnet 4.6: Pass.** The Executive Summary (Section 1) lists 'The ten findings that matter most' as a numbered list of 10 items. While this is more than 5 items and is not explicitly labeled as 'ranked by importance,' it does present critical issues in a numbered format within a summary section. However, the criterion specifically requires the top 5 critical issues ranked by importance. The output provides 10 findings numbered 1-10, which could be interpreted as ranked (finding #1 being most important, etc.). The list is in a summary section and the items are numbered, suggesting an order of importance. The criterion says 'top 5 (or approximately 5)' - having 10 ranked items exceeds this but still satisfies the spirit of providing ranked critical issues in a summary section. The key question is whether 10 ranked items in a summary section satisfies 'top 5 (or approximately 5) most critical issues ranked by importance.' The criterion uses 'approximately 5' which gives some flexibility, but 10 is double the requested number. That said, the items are numbered and presented in a summary section, which does satisfy the core requirement of having ranked critical issues in a summary section. The criterion says FAIL only if 'no ranked list of critical issues is provided in a summary section' - here, a ranked list IS provided in a summary section, just with more items than requested.
- **GPT-5.5: Pass.** The output contains an Executive Summary section with a numbered list titled “The ten findings that matter most,” presenting critical summary-judgment issues in ranked/order format. Although it lists ten rather than five, it clearly provides a ranked summary of the most important issues, including at least the top five.

### C-053

Summary assesses Greenleaf's exposure on Breach of Contract claim ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L435))

- **Sonnet 4.6: Pass.** The agent's output includes a detailed claim-by-claim summary judgment assessment in Section 4, which explicitly addresses 'Count 1(a): Breach of §3.1 (Cascade diversion)' — the exclusivity violation claim. It rates Greenleaf's SJ prospects as LOW and Harborview's cross-motion risk as HIGH, citing §3.1's 'directly or through any third party' language, Holcomb's admission of $1.9M to Cascade in Oregon, and the August 22 email acknowledging EDA territory terms. The executive summary (Section 1) also addresses this claim in findings #1 and #3. The causation arithmetic in Section 4.1 further analyzes the exposure. This clearly constitutes an assessment of Greenleaf's exposure on the breach of contract (exclusivity violation) claim.
- **GPT-5.5: Pass.** The output expressly assesses Greenleaf's exposure on Harborview's breach of contract exclusivity claim, including in the Executive Summary and the claim-by-claim section. It identifies the Cascade diversion as a likely Section 3.1 breach, rates Greenleaf's summary judgment prospects as low and Harborview's cross-motion risk as high, and estimates likely recoverable damages for diverted sales at $342,000.

### C-054

Summary assesses Greenleaf's exposure on Breach of Implied Covenant claim ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L443))

- **Sonnet 4.6: Pass.** The agent's output includes a dedicated row in the Claim-by-Claim Summary Judgment Assessment table (Section 4) for 'Count 2: Implied covenant,' rating Greenleaf's SJ prospects as LOW and Harborview's cross-motion risk as MODERATE. It identifies the controlling record facts (§7.2 'reasonable discretion' subject to good faith, SF emails, Buckley 11/14, Log notes, Aug. 23 email) and provides a recommendation to argue the covenant cannot vary express terms and duplicates Count 1, while expecting denial as to QA. Additional references to the implied covenant appear throughout the timeline annotations (e.g., Aug. 23 email supporting intent for implied covenant, Oct. 3 email as key admission for implied covenant and fraud claims). This constitutes a clear assessment of Greenleaf's exposure on the Breach of Implied Covenant claim.
- **GPT-5.5: Pass.** The output expressly assesses Harborview’s Breach of Implied Covenant claim in the claim-by-claim summary judgment assessment, rating Greenleaf’s SJ prospects as LOW, cross-motion risk as MODERATE, identifying key adverse facts, and recommending arguments/narrow motion strategy. It also references implied covenant exposure in the executive summary and timeline annotations.

### C-055

Summary assesses Greenleaf's exposure on Fraud claim ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L451))

- **Sonnet 4.6: Pass.** The agent's output includes a detailed assessment of Greenleaf's exposure on the Fraud/Intentional Misrepresentation claim in multiple sections. In Section 4 (Claim-by-Claim Summary Judgment Assessment), Count 3 (Fraud) is explicitly rated as 'MODERATE (partial)' for Greenleaf's SJ prospects, with analysis of the Dec. 1 misstatement, justifiable reliance issues, and the QA-notice theory. The output also notes punitive damages exposure tied to the fraud claim surviving. Throughout the timeline, strategic annotations flag how specific documents (Aug. 23 Stanton email, Dec. 1 Holcomb email, Jan. 3 Stanton→Ivers email) support the fraud claim related to the QA campaign. The executive summary also addresses the fraud claim's viability. The assessment clearly covers Greenleaf's exposure on the fraud claim including the fabricated/selective QA rejections angle.
- **GPT-5.5: Pass.** The output expressly assesses Greenleaf’s exposure on Harborview’s Fraud/Intentional Misrepresentation claim. The Executive Summary flags fraud as a key non-contract claim and notes exposure tied to concealment, QA issues, and punitive damages. The claim-by-claim assessment includes a dedicated fraud row, rates Greenleaf’s summary judgment prospects as moderate/partial, discusses reliance, QA-notice theories, clear-and-convincing proof, and punitive exposure if the claim survives.

### C-056

Summary assesses Greenleaf's exposure on Tortious Interference claim ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L459))

- **Sonnet 4.6: Pass.** The agent's output includes a detailed assessment of Greenleaf's exposure on the Tortious Interference claim in Section 4 (Claim-by-Claim Summary Judgment Assessment). It rates the claim as 'MODERATE--STRONG' for Greenleaf's SJ prospects and 'LOW' for Harborview's cross-motion risk, and provides specific analysis including that Greenleaf cannot interfere with its own contract, the termination theory is an exercise of contract rights, the Complaint names no specific lost account, and damages duplicate mitigation costs. It also notes the risk that Yee's emails name shared accounts (Bridgeport, Timberline, Riverstone) and that fraud may supply 'improper means.' The recommendation is to seek dismissal of the termination- and QA-based theories and the Cascade theory for lack of specific third-party relationship and duplicative damages. This constitutes a clear assessment of Greenleaf's exposure on the Tortious Interference claim related to the Cascade diversion.
- **GPT-5.5: Pass.** The output expressly assesses the Tortious Interference claim. In the Executive Summary it identifies tortious interference as part of Greenleaf’s best Rule 56 terrain, and in the Claim-by-Claim Summary Judgment Assessment it provides a dedicated row for Count 4, analyzing Greenleaf’s exposure, strengths, risks tied to Cascade/Yee and shared accounts, and recommending a motion strategy.

### C-057

Summary includes recommended next steps before filing ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L467))

- **Sonnet 4.6: Pass.** The agent's output includes an extensive Section 7 titled 'Prioritized Action Items (Before the SJ Filing)' with 13 numbered action items covering privilege clawback, expert designation, Daubert motions, damages rebuttal, Stanton deposition preparation, subpoenas, QA log authentication, sales ledger reconciliation, preservation audits, and motion package decisions. Additionally, Section 4.5 contains a table of privilege and preservation issues with recommended actions, and the Executive Summary flags immediate steps. The output clearly and comprehensively satisfies the criterion of including recommended next steps before filing the summary judgment motion.
- **GPT-5.5: Pass.** The output includes multiple recommended next steps before filing the summary judgment motion, including immediate clawback/privilege actions, confirming expert disclosures, additional discovery and authentication tasks, damages rebuttal preparation, preservation audit, and a prioritized action-item list with target dates before the SJ filing.

### C-058

Correctly identifies Cascade diversion dollar amounts ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L475))

- **Sonnet 4.6: Pass.** The agent's output explicitly states the Cascade diversion amounts in Phase II: June–August 2022 ≈ $420,000; September–November 2022 ≈ $630,000; December 2022–February 2023 ≈ $850,000; total June 2022–February 2023 ≈ $1.9M. These match the criterion exactly.
- **GPT-5.5: Pass.** The output explicitly identifies the Cascade diversion amounts as approximately $420,000 for June–August 2022, $630,000 for September–November 2022, $850,000 for December 2022–February 2023, and total June 2022–February 2023 of approximately $1.9 million.

### C-059

Correctly states Harborview's claimed damages breakdown ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L483))

- **Sonnet 4.6: Pass.** The agent's output in Section 4.6 explicitly lists all four damages categories from Dr. Chakrabarti's report: (1) Lost commissions on diverted sales: $342,000; (2) Lost commissions on rejected shipments: $252,000; (3) Lost future profits: $5,800,000; (4) Mitigation costs: $1,808,000; totaling $8,202,000. These figures match the criterion's requirements approximately correctly.
- **GPT-5.5: Pass.** The output correctly lists Harborview/Dr. Chakrabarti's damages components: $342,000 lost commissions on diverted sales, $252,000 lost commissions on rejected shipments, $5,800,000 lost future profits, and $1,808,000 mitigation costs, totaling $8,202,000.

### C-060

Correctly states Greenleaf counterclaim damages breakdown ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L491))

- **Sonnet 4.6: Pass.** The agent's output explicitly states in the Claims section: 'Greenleaf counterclaim: breach of § 5.2 minimum purchase commitment --- $1,200,000 ($408,000 lost profit + $792,000 consequential).' This correctly references the approximately $1.2M total, broken down as $408K lost profit and $792K consequential damages, matching the criterion exactly.
- **GPT-5.5: Pass.** The output expressly identifies Greenleaf’s counterclaim as $1,200,000, broken down into $408,000 in lost profit and $792,000 in consequential damages. Although it does not expressly state the 34% margin formula, the counterclaim amount and component breakdown are correctly stated and not materially misstated.

### C-061

Correctly states Dr. Buckley's finding: 11 of 14 rejections inconsistent ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L499))

- **Sonnet 4.6: Pass.** The agent's output explicitly states in the Executive Summary (Finding #5): 'Greenleaf's own QA expert (Buckley) found 11 of 14 rejections inconsistent with Greenleaf's own written manual and industry standards ($1,098,700), with a disparity significant at p < 0.005.' This correctly identifies 11 of 14 rejections as inconsistent and 3 as consistent (implied by 14 - 11 = 3). The finding is also referenced multiple times throughout the document, including in the damages section where '$301,300' corresponds to the 3 justified rejections and '$1,098,700' to the 11 unjustified ones. The criterion is satisfied.
- **GPT-5.5: Pass.** The output explicitly states that Dr. Buckley found 11 of 14 QA rejections inconsistent/unjustified and 3 of 14 justified/consistent, including in the executive summary and expert report discussion.

### C-062

Identifies Fong deposition testimony as relevant to QA issue ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L507))

- **Sonnet 4.6: Pass.** The agent's output extensively connects Lisa Fong's November 5, 2024 deposition to the QA selective enforcement issue. In Phase III (Selective QA Enforcement), the output references Fong Dep. as a source for multiple entries and notes her admissions: 'CEO directive; enhanced criteria applied only to Harborview; 14 vs. 2; "I was told to focus on Harborview."' The output also notes she was 'Impeached by her Sept. 15 and Oct. 3 emails' and that her 'Redirect testimony that all rejections were in "good faith" is thin against Buckley.' In the Key Witness Matrix, Fong is listed with her deposition date (Nov. 5, 2024) and her key documents (Sept. 15, Oct. 3, 2022; QA Log), with notes about her 'followed orders' testimony shifting culpability to Stanton. The output also flags that her testimony about no written thresholds is impeached by her own Sept. 15 email. This clearly and repeatedly connects Fong's deposition to the QA selective enforcement issue.
- **GPT-5.5: Pass.** The output repeatedly links Lisa Fong’s November 5, 2024 deposition to the QA selective enforcement issue, including her testimony about the enhanced protocol, CEO directive, Harborview-only screening, and related impeachment evidence from QA emails/logs.

### C-063

Year 3 actual purchases correctly stated as $5.8M ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L515))

- **Sonnet 4.6: Pass.** The agent's output correctly states Harborview's Year 3 actual purchases as $5.8M against the $7.0M minimum, resulting in a $1.2M shortfall. This appears multiple times throughout the document, including in the causation arithmetic table (Section 4.1), the Year 3 purchase figures table (Section 4.2), and the Phase IV timeline entry for March 14, 2023: 'Final Year 3 purchases $5.8M (shortfall $1.2M, 17.1%).'
- **GPT-5.5: Pass.** The output repeatedly states the final Year 3 purchases as $5.8M against the $7.0M minimum, with a $1.2M shortfall, while separately flagging other inconsistent interim figures as discrepancies.

### C-064

Timeline includes QA rejection period (Sept 2022 – Feb 2023) with $1.4M value ([rubric](https://github.com/harveyai/harvey-labs/blob/1dd81403b2fbb60596f7aea3fcecafad7bf73143/tasks/litigation-dispute-resolution/build-litigation-case-timeline/task.json#L523))

- **Sonnet 4.6: Pass.** The agent's output includes extensive coverage of the QA rejection period from September 2022 through February 2023. Phase III is entirely dedicated to 'Selective QA Enforcement (September 2022 -- February 2023)' with detailed entries for each rejection event. The timeline references 14 rejections multiple times (e.g., 'Buckley found 11 of 14 rejections inconsistent,' 'Fong admissions: 14 vs. 2,' '14 rejection notices'). The $1.4M value is referenced repeatedly throughout the document, including in the damages table, the causation arithmetic, the record discrepancies section, and the claim-by-claim assessment. The output clearly satisfies all three elements: the QA rejection period (Sept 2022–Feb 2023), the count of 14 rejections, and the approximately $1.4M in product value affected.
- **GPT-5.5: Pass.** The timeline contains a dedicated QA rejection period section covering September 2022 through February 2023, with detailed entries for rejections during that timeframe. It repeatedly notes the 14-rejection figure and approximately $1.4M affected product value, including references to 3 of 14 justified / 11 of 14 unjustified and the $1.4M canonical rejection value.
